SelectQuote prioritizes cash flow and deleveraging in fiscal 2027, guiding for lower revenues but more than $60 million in operating cash flow.
SelectQuote, Inc. (SLQT) Q4 2026 Earnings Call Transcript
SelectQuote NYSE: SLQT reported fiscal 2026 revenue growth, improved profitability and a $44 million year-over-year increase in operating cash flow, while outlining a fiscal 2027 plan centered on cost efficiency, cash generation and lower leverage rather than top-line expansion.
SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
SelectQuote (SLQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SelectQuote (SLQT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
The heavy selling pressure might have exhausted for SelectQuote (SLQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript
SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT's fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins.
SelectQuote faces mounting challenges, including weaker growth in its core SelectRx segment and heightened industry headwinds impacting policy sales and retention. SLQT's revenue mix is shifting toward recurring pharmacy benefits, but razor-thin margins and recent member losses raise concerns about long-term profitability. Despite trading at a low 5x EV/FY26 adjusted EBITDA, SLQT's high debt load and uncertain outlook make its valuation less compelling.